Back to top
more

Repligen (RGEN)

(Delayed Data from NSDQ)

$120.95 USD

120.95
677,719

+0.13 (0.11%)

Updated Jul 10, 2024 04:00 PM ET

After-Market: $121.39 +0.44 (0.36%) 5:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Should Vanguard S&P MidCap 400 Growth ETF (IVOG) Be on Your Investing Radar?

Style Box ETF report for IVOG

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?

Smart Beta ETF report for RFG

Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat

Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.

Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates

Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.

Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 24.62% and 3.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More

Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.

Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Industry Outlook Highlights: Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen

Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen are highlighted in this Industry Outlook article.

Ekta Bagri headshot

4 Top Biotech Stocks to Gain Amid Industry Challenges

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX and RGEN well amid the volatility.

Gamida (GMDA) Up on Omidubicel BLA Rolling Submission Plan

The FDA agrees to the initiation of rolling submission of Gamida's (GMDA) BLA for its lead blood cancer candidate, omidubicel. The stock rises more than 22% on in response.

Should Vanguard S&P MidCap 400 Growth ETF (IVOG) Be on Your Investing Radar?

Style Box ETF report for IVOG

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

Vertex (VRTX) Kaftrio Gets Europe Nod for CF in Children

The European Commission approves Vertex's (VRTX) triple combination therapy, Kaftrio, in combination with Kalydeco for treating cystic fibrosis in children aged between six and 11 years.

Down 16.5% in 4 Weeks, Here's Why Repligen (RGEN) Looks Ripe for a Turnaround

Repligen (RGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why You Should Hold Onto Acadia Healthcare (ACHC) Now

Acadia Healthcare (ACHC) is poised for growth due to higher revenues driven by solid demand for behavioral health services, multiple JVs with established healthcare systems and debt repayment efforts.

J&J (JNJ) Seeks FDA Approval for Myeloma Drug Teclistamab

J&J (JNJ) submits a Biologics License Application, seeking approval for its bispecific antibody candidate teclistamab as a treatment option for the heavily pretreated multiple myeloma patients.

Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?

Smart Beta ETF report for RFG

Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS

Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.

Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day

Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day